BGM Group vs Verrica Pharmaceuticals
BGM Group reported revenue of $38 million in fiscal 2025, about the same as Verrica Pharmaceuticals' $36 million in fiscal 2025. BGM Group's revenue grew 51.1% in its latest year, and Verrica Pharmaceuticals' grew 370.2%. BGM Group had an operating margin of -33.2%, against -34.2% at Verrica Pharmaceuticals. Free cash flow was −$4 million at BGM Group and −$18 million at Verrica Pharmaceuticals. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.
Side by side
| BGM Group | Verrica Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Sep 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $38M | $36M |
| Revenue growth | 51.1% | 370.2% |
| Revenue growth a year, last 5 years | −5.4% | — |
| Gross margin | 16.6% | — |
| Operating margin | −33.2% | −34.2% |
| Net margin | −52.6% | −50.3% |
| Free cash flow | −$4M | −$18M |
| Free cash flow margin | −10.4% | −49.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1,467.3% | 105.6% |
| Last close | $8.00 | $2.88 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $18.2 million, sold $0 |
| Piotroski F-score | — | 5 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BGM GroupVerrica Pharmaceuticals
Operating margin
Percent of revenue
BGM GroupVerrica Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BGM GroupVerrica Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BGM Group and Verrica Pharmaceuticals pages.